Your browser is no longer supported. Please, upgrade your browser.
Settings
GILD Gilead Sciences Inc. daily Stock Chart
GILD [NASD]
Gilead Sciences Inc.
IndexS&P 500 P/E6.68 EPS (ttm)10.78 Insider Own0.30% Shs Outstand1.33B Perf Week-1.13%
Market Cap95.43B Forward P/E6.63 EPS next Y10.86 Insider Trans-21.54% Shs Float1.31B Perf Month-2.73%
Income15.08B PEG- EPS next Q2.62 Inst Own76.10% Short Float1.19% Perf Quarter-7.17%
Sales31.58B P/S3.02 EPS this Y62.00% Inst Trans-5.32% Short Ratio1.61 Perf Half Y-13.72%
Book/sh12.76 P/B5.64 EPS next Y-5.34% ROA29.30% Target Price95.74 Perf Year-27.88%
Cash/sh9.26 P/C7.78 EPS next 5Y-0.64% ROE93.70% 52W Range71.39 - 103.08 Perf YTD-27.65%
Dividend1.88 P/FCF6.42 EPS past 5Y48.30% ROI45.90% 52W High-30.13% Beta1.22
Dividend %2.61% Quick Ratio1.80 Sales past 5Y32.60% Gross Margin86.50% 52W Low0.88% ATR1.53
Employees8000 Current Ratio1.90 Sales Q/Q-9.60% Oper. Margin60.80% RSI (14)37.98 Volatility1.77% 2.02%
OptionableYes Debt/Eq1.60 EPS Q/Q-18.70% Profit Margin47.70% Rel Volume1.28 Prev Close72.78
ShortableYes LT Debt/Eq1.56 EarningsNov 01 AMC Payout16.40% Avg Volume9.63M Price72.02
Recom2.20 SMA20-3.86% SMA50-3.73% SMA200-12.79% Volume12,324,818 Change-1.04%
Nov-14-16Initiated Stifel Buy $100
Nov-08-16Initiated Mizuho Buy $88
Nov-02-16Reiterated RBC Capital Mkts Outperform $95 → $90
Oct-25-16Reiterated Jefferies Buy $93 → $95
Oct-03-16Reiterated RBC Capital Mkts Outperform $105 → $95
Sep-27-16Downgrade Leerink Partners Outperform → Mkt Perform $112 → $94
Sep-12-16Initiated Berenberg Buy $112
Sep-06-16Upgrade Jefferies Hold → Buy
Jul-29-16Downgrade Argus Buy → Hold
Jul-26-16Reiterated RBC Capital Mkts Outperform $120 → $105
Jul-26-16Downgrade Needham Buy → Hold
Jun-01-16Initiated Gabelli & Co Buy $109
Apr-29-16Reiterated UBS Buy $130 → $118
Apr-29-16Downgrade Maxim Group Buy → Hold
Mar-16-16Reiterated Leerink Partners Outperform $130 → $127
Feb-25-16Initiated Citigroup Buy $110
Feb-12-16Reiterated Maxim Group Buy $137 → $115
Feb-03-16Reiterated RBC Capital Mkts Outperform $130 → $120
Feb-03-16Reiterated Piper Jaffray Overweight $134 → $114
Feb-03-16Reiterated Oppenheimer Outperform $124 → $120
Dec-08-16 04:43PM  Lululemon and Tailored Brands surge; Gilead and Grumman drop
04:18PM  Health care sector suffers: Time to buy the dip?
04:04PM  FitBit, Gilead Sciences in Thursdays 52-Week Low Club at 24/7 Wall St.
01:00PM  This May Be 2016's Top Stock-Selection Model
10:08AM  Gilead Sciences: We Can Get Past This at Barrons.com
08:11AM  Gilead Submits New Drug Application to U.S. Food and Drug Administration for the Investigational Single Tablet Regimen Sofosbuvir/Velpatasvir/Voxilaprevir Business Wire
08:00AM  Gilead's CEO Apologetic About Sovaldi's $1,000 Per Pill Price Tag at Forbes
Dec-07-16 03:48PM  Gilead Sciences Inc.'s Worst Moves in 2016 at Motley Fool
Dec-06-16 08:33AM  3 Beaten-Up Healthcare Stocks: Are They Bargains? at Motley Fool
07:05AM  Trump's corporate tax holiday could spur pharma M&A Reuters
Dec-05-16 01:24PM  Gilead Sciences: Nothing to See HereExcept the Need for M&A at Barrons.com
08:23AM  1 Quote Reveals Why Gilead Sciences Hasn't Bought Anybody Yet at Motley Fool
Dec-04-16 06:05PM  5 Healthcare Stocks Billionaires Love The Most at Insider Monkey
01:57PM  [$$] NHS to launch three-year anti-HIV PrEP trial at Financial Times
06:49AM  3 Reasons Why Incyte Corporation Stock Could Soar in 2017 at Motley Fool
05:37AM  5 Dividend Stocks to Buy in December at Motley Fool
Dec-02-16 04:41PM  Forget Pfizer: Here Are 3 Better Dividend Stocks at Motley Fool
10:57AM  Gilead Sciences: Forget About Hepatitis CEveryone Else Is at Barrons.com
08:04AM  What Do Analysts Recommend for Gilead Sciences Stock?
Dec-01-16 11:35AM  Gilead Sciences, Inc. (GILD) Begins A Process That Could Alleviate Its Problems at Insider Monkey
11:04AM  How Could Gilead Sciences Restore Its Growth?
10:18AM  Gilead Sciences, Inc.'s $10 Billion Mistake at Motley Fool
10:04AM  How Much Could Gilead Sciencess Revenues Fall beyond 2016?
08:04AM  Epclusa: Gilead Sciencess Pan-Genotype Product
Nov-30-16 04:32PM  5 Things Gilead Sciences' CEO Just Said That You Need to Know at Motley Fool
11:56AM  Gilead Pushes Truvada HIV Prevention Drug (GILD) at Investopedia
11:04AM  Mercks Zepatier Put Pricing Pressure on Gilead Sciencess Harvoni
10:04AM  Scrutinizing the HCV Market Based on Genotypes
08:04AM  Could There Be a Steep Fall for Gilead Sciencess HCV Franchise?
06:02AM  Hedge Funds Hate These 5 Huge Stocks -- Should You Sell Them?
01:00AM  Switching course, Gilead markets HIV drug for prevention
Nov-29-16 04:15PM  Winners & losers from repealing Obamacare
02:28PM  Gilead Is a Strong Contrarian 'Buy'
12:17PM  Gilead Sciences, Inc. (GILD) Takes Lead Against AbbVie Inc (ABBV) On Crohns Disease Treatment at Insider Monkey
12:04PM  Visualizing Financial Trends With Interactive Charts, Other Topics
11:04AM  How Did Gilead Sciencess HCV Business Perform across Geographies?
10:04AM  The US is Gilead Sciencess Major Market
09:17AM  Injections, implants tested as new weapons to prevent HIV
08:04AM  How Could TAF-Based Regimen Drive Gilead Sciencess Growth?
Nov-28-16 02:13PM  Cramer's lightning round: Why I'm wary of Gilead's growth at CNBC
12:32PM  Gilead Launches Phase 3 Crohn's Study (GILD, GLPG) at Investopedia
11:06AM  Gilead Sciences Holds a Broader HIV Portfolio
10:05AM  Gilead Sciencess HCV Fall Was Partially Offset by HIV Business
08:05AM  Is Gilead Sciences Stock Oversold?
07:35AM  Short Sellers Grow More Aggressive on Major Biotechs
Nov-26-16 12:13AM  [$$] Northern Right Capital Sees Promise in PRGX at Barrons.com
Nov-25-16 01:14PM  Gurus Invest in Undervalued Biotech Stocks
08:32AM  J&J (JNJ) Reportedly Approaches Actelion for Acquisition
Nov-24-16 07:00AM  Here is What Hedge Funds Think about Gilead Sciences, Inc. (GILD) at Insider Monkey
Nov-23-16 04:44PM  What Happened in Biotech in 2016? at Motley Fool
01:59PM  When Will Gilead Sciences' Unlucky Streak End? at Motley Fool
01:49PM  Weighing In On Galapagos NV (ADR) (GLPG)s Lead Studies at Insider Monkey
11:39AM  Matinas BioPharma Holdings Inc (MTNB) Can Take A $350M Antifungal Market From Gilead Sciences, Inc. (GILD) at Insider Monkey
09:02AM  The Worst Growth Dividend Stocks of 2016 at Motley Fool
08:42AM  3 Inexpensive Top Stocks You've Overlooked This Fall at Motley Fool
08:24AM  Galapagos (GLPG) Filgotinib in Phase III for Crohn's Disease
08:10AM  Gilead Sciences Canada, Inc., is awarded prestigious Prix Galien Canada Innovative Product Award CNW Group
07:30AM  Are Biogen and Gilead Sciences in Denial? at Motley Fool
06:31AM  Biotech Stock Roundup: Acorda Stops Ampyra PSWD Development, CRL for Spectrum's Qapzola
Nov-22-16 04:01PM  Lilly Poised For Big December On Alzheimer's Data, Diabetes Ruling
10:04AM  Inside Bristols Key to Success: Multiple Labels for Opdivo
06:02AM  Attention, Biotech Investors: Black Friday Is Already Here at Motley Fool
Nov-21-16 04:07PM  Amgen, Biogen, Celgene Eye M&A In Trump's 'Pro-Biotech' World
01:19PM  5 Most Expensive Medicare Drugs -- and Which Companies Are Getting Rich From Them at Motley Fool
12:50PM  Whats Next At GlobeImmune Inc (GBIM)? at Insider Monkey
07:46AM  The No. 1 Healthcare Concern Americans Want Donald Trump to Fix -- and It's Not Obamacare at Motley Fool
Nov-18-16 09:00PM  No to Closed-End Muni Bond Funds; Cara on a Run: Best of Kass
05:09PM  3 Embarrassingly Cheap Dividend Stocks at Motley Fool
12:40PM  Gilead CEO Resigns, Dumps GlobeImmune Pact (GILD) at Investopedia
11:01AM  [$$] Gilead Now More Likely to Buy Incyte? at Barrons.com
10:24AM  Gilead Sciences: Buy 'Regeneron Lite'Or Just Buy Regeneron? at Barrons.com
10:22AM  Gilead Bone Marrow Drug Fails Phase 2 (GILD, INCY) at Investopedia
12:21AM  [$$] After Rough Patch, Gilead Shouldnt Succumb to Deal Pressure at The Wall Street Journal
Nov-17-16 05:25PM  Gilead Sciences: Dirt Cheap With Lots of Growth Potential
04:11PM  Gilead Could Scoop Up Incyte After Cancer Drug Proves 'Not Good Enough'
01:24PM  [$$] After Rough Patch,Gilead Shouldn't Succumb to Deal Pressure at The Wall Street Journal
01:02PM  Bad News for Gilead Sciences Is Good News for Incyte at Motley Fool
10:44AM  Does Gilead Sciences Pass Warren Buffett's Test? at Motley Fool
09:35AM  Gilead Sciences: Failure, Failure, Failureand the Case For Upside at Barrons.com
09:20AM  Don't Count on a Rally for Gilead
08:21AM  Gilead Reports Phase III Myelofibrosis Data on Momelotinib
06:59AM  3 Potential Acquisition Targets for Gilead Sciences, Inc. at Motley Fool
06:36AM  Hey Gilead, Stop Developing Drugs and Start Buying Biotech Companies -- Now!
Nov-16-16 05:00PM  Gilead Sciences Announces Promotion of James R. Meyers to Executive Vice President, Worldwide Commercial Operations Business Wire
04:15PM  Gilead Announces Top-Line Results From Two Phase 3 Studies Evaluating Momelotinib for Patients With Myelofibrosis Business Wire
03:45PM  Sell These 5 Stocks Now Before its Too Late
11:01AM  Here Are 2 Excellent Dividend-Paying Drug Stocks to Buy Right Now
08:12AM  Biotech Stock Roundup: Biotech Stocks Soar on Election Results, Gilead HBV Drug Approved
Nov-15-16 08:01PM  Buyers clubs for cheaper drugs AAP
05:00PM  Gilead Sciences to Present at the Annual Piper Jaffray Healthcare Conference on Tuesday, November 29 Business Wire
04:25PM  Gilead Could Add $1 Billion On NASH Drug, But Mechanism 'Puzzling'
02:35PM  Gilead Sciences' Miracle Drug Combination
02:11PM  Gilead Sciences: Encouraging? Inconclusive? Yes. at Barrons.com
01:04PM  GILEAD SCIENCES INC Financials
11:40AM  ValueWorks Top Pick From Each of 5 Prominent Sectors: Gilead (GILD), Boeing (BA), More at Insider Monkey
09:53AM  Gilead, Buy HIV, Get Hepatitis C for Free
12:23AM  [$$] Medicare Identifies Which Prescription Drugs Were Costliest in 2015 at The Wall Street Journal
Nov-14-16 07:08PM  Medicare Identifies Which Prescription Drugs Were Costliest in 2015
05:24PM  These drugs had the highest price increases in 2015 according to the government agency that pays for them
04:57PM  Gilead Responds To CMS Blog Highlighting High Cost Of Harvoni: Most Payers Receive Substantial Discounts Off The List Price
Gilead Sciences Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical needs in North America, South America, Europe, and the Asia-Pacific. The company's products include Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus (HIV) infection in adults; and Harvoni, Sovaldi, Viread, and Hepsera products for the treatment of liver diseases. It also offers Zydelig, a PI3K delta inhibitor, in combination with rituximab, for the treatment of certain blood cancers; Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B. In addition, the company provides other products, such as AmBisome, an antifungal agent to treat serious invasive fungal infections; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it has product candidates in various stages of development for the treatment of HIV/AIDS and liver diseases, such as hepatitis B virus and hepatitis C virus; inflammation/oncology; serious cardiovascular; and respiratory conditions, as well as diabetic nephropathy and ebola. The company markets its products through its commercial teams and/or in conjunction with third-party distributors and corporate partners. Gilead Sciences Inc. has collaboration agreements with Bristol-Myers Squibb Company, Janssen R&D Ireland, Japan Tobacco Inc., and Galapagos NV. The company was founded in 1987 and is headquartered in Foster City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MARTIN JOHN CExecutive ChairmanDec 01Option Exercise16.40100,0001,639,5003,231,096Dec 05 12:54 PM
WILSON GAYLE EDirectorDec 01Option Exercise0.002,1470107,486Dec 05 07:59 PM
MARTIN JOHN CExecutive ChairmanDec 01Sale73.33100,0007,332,8703,131,096Dec 05 12:54 PM
MADIGAN JOHN WDirectorNov 18Option Exercise20.71105,0002,174,025121,761Nov 22 02:45 PM
MADIGAN JOHN WDirectorNov 18Sale74.86105,0007,860,05916,761Nov 22 02:45 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffNov 09Sale79.0010,000790,000122,964Nov 14 01:03 PM
MARTIN JOHN CExecutive ChairmanNov 01Option Exercise16.40100,0001,639,5003,231,096Nov 03 06:10 PM
MARTIN JOHN CExecutive ChairmanNov 01Sale73.76100,0007,376,0463,131,096Nov 03 06:10 PM
MARTIN JOHN CExecutive ChairmanOct 03Option Exercise16.40100,0001,639,5003,231,096Oct 05 12:52 PM
MARTIN JOHN CExecutive ChairmanOct 03Sale77.63100,0007,762,9613,131,096Oct 05 12:52 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffSep 22Sale81.845,000409,220132,964Sep 26 04:54 PM
MILLIGAN JOHN FPresident and CEOSep 06Option Exercise20.7470,0001,451,8001,128,963Sep 08 01:35 PM
MILLIGAN JOHN FPresident and CEOSep 06Sale77.7470,0005,442,0801,058,963Sep 08 01:35 PM
MARTIN JOHN CExecutive ChairmanSep 01Option Exercise16.40100,0001,639,5003,231,096Sep 06 02:40 PM
MARTIN JOHN CExecutive ChairmanSep 01Sale77.48100,0007,748,3633,131,096Sep 06 02:40 PM
Lofton Kevin EDirectorAug 24Sale81.973,500286,8990Aug 25 05:05 PM
Carter Paul RutherfordEVP Commercial OpsAug 01Option Exercise39.132,00078,25564,305Aug 03 04:48 PM
MARTIN JOHN CExecutive ChairmanAug 01Option Exercise16.40100,0001,639,5004,119,727Aug 03 04:51 PM
MILLIGAN JOHN FPresident and CEOAug 01Option Exercise20.7470,0001,451,8001,128,963Aug 03 04:53 PM
MILLIGAN JOHN FPresident and CEOAug 01Sale70.9470,0004,965,5901,058,963Aug 03 04:53 PM
MARTIN JOHN CExecutive ChairmanAug 01Sale80.50100,0008,049,7854,019,727Aug 03 04:51 PM
Carter Paul RutherfordEVP Commercial OpsAug 01Sale79.812,000159,62062,305Aug 03 04:48 PM
Carter Paul RutherfordEVP Commercial OpsJul 31Option Exercise0.002,500063,622Aug 02 04:43 PM
MILLIGAN JOHN FPresident and CEOJul 05Option Exercise16.40112,0001,836,2401,170,963Jul 07 02:50 PM
MILLIGAN JOHN FPresident and CEOJul 05Sale84.33112,0009,444,9211,058,963Jul 07 02:50 PM
Carter Paul RutherfordEVP Commercial OpsJul 01Option Exercise24.912,00049,81063,122Jul 06 01:26 PM
MARTIN JOHN CExecutive ChairmanJul 01Option Exercise16.40100,0001,639,5004,119,727Jul 06 01:28 PM
MARTIN JOHN CExecutive ChairmanJul 01Sale84.73100,0008,472,5234,019,727Jul 06 01:28 PM
Carter Paul RutherfordEVP Commercial OpsJul 01Sale83.122,000166,25061,122Jul 06 01:26 PM
MILLIGAN JOHN FPresident and CEOJun 06Option Exercise16.40112,0001,836,2401,170,963Jun 08 06:59 PM
MILLIGAN JOHN FPresident and CEOJun 06Sale86.94112,0009,736,7791,058,963Jun 08 06:59 PM
Carter Paul RutherfordEVP Commercial OpsJun 01Option Exercise24.912,00049,81063,122Jun 03 04:46 PM
MARTIN JOHN CExecutive ChairmanJun 01Option Exercise16.40100,0001,639,5004,119,727Jun 03 04:51 PM
MARTIN JOHN CExecutive ChairmanJun 01Sale86.72100,0008,671,9504,019,727Jun 03 04:51 PM
Carter Paul RutherfordEVP Commercial OpsJun 01Sale87.022,000174,04061,122Jun 03 04:46 PM
Carter Paul RutherfordEVP Commercial OpsMay 31Option Exercise33.8857,0921,934,021118,214Jun 02 04:35 PM
Carter Paul RutherfordEVP Commercial OpsMay 31Sale86.8557,0924,958,60061,122Jun 02 04:35 PM
MARTIN JOHN CExecutive ChairmanMay 02Option Exercise16.40100,0001,639,5004,119,727May 04 02:44 PM
MILLIGAN JOHN FPresident and CEOMay 02Option Exercise16.40112,0001,836,2401,170,963May 04 02:49 PM
Carter Paul RutherfordEVP Commercial OpsMay 02Option Exercise39.132,00078,25563,122May 04 04:23 PM
Carter Paul RutherfordEVP Commercial OpsMay 02Sale88.722,000177,44861,122May 04 04:23 PM
MILLIGAN JOHN FPresident and CEOMay 02Sale87.71112,0009,823,9541,058,963May 04 02:49 PM
MARTIN JOHN CExecutive ChairmanMay 02Sale87.82100,0008,781,6944,019,727May 04 02:44 PM
Alton Gregg HEVP, Corp & Med AffairsApr 19Option Exercise26.9935,874968,239177,964Apr 21 01:28 PM
Alton Gregg HEVP, Corp & Med AffairsApr 19Sale100.0140,0004,000,574137,964Apr 21 01:28 PM
MILLIGAN JOHN FPresident and CEOApr 04Option Exercise16.40112,0001,836,2401,170,963Apr 05 07:30 PM
MILLIGAN JOHN FPresident and CEOApr 04Sale94.59112,00010,593,9041,058,963Apr 05 07:30 PM
MARTIN JOHN CExecutive ChairmanApr 01Option Exercise16.40100,0001,639,5004,119,727Apr 05 07:49 PM
Carter Paul RutherfordEVP Commercial OpsApr 01Option Exercise24.912,00049,81063,122Apr 05 06:36 PM
Carter Paul RutherfordEVP Commercial OpsApr 01Sale91.342,000182,68061,122Apr 05 06:36 PM
MARTIN JOHN CExecutive ChairmanApr 01Sale93.24100,0009,323,5074,019,727Apr 05 07:49 PM
Alton Gregg HEVP, Corp & Med AffairsApr 01Sale91.235,000456,158142,090Apr 05 07:45 PM
Alton Gregg HEVP, Corp & Med AffairsMar 14Sale90.005,000450,000147,090Mar 15 07:31 PM
MARTIN JOHN CChairman and CEOMar 01Option Exercise16.40100,0001,639,5004,119,727Mar 03 02:47 PM
MILLIGAN JOHN FPresident, COO and DirectorMar 01Option Exercise16.40112,0001,836,2401,170,963Mar 03 02:54 PM
Carter Paul RutherfordEVP Commercial OpsMar 01Option Exercise24.912,00049,81063,122Mar 03 03:10 PM
MILLIGAN JOHN FPresident, COO and DirectorMar 01Sale87.79112,0009,832,9951,058,963Mar 03 02:54 PM
Carter Paul RutherfordEVP Commercial OpsMar 01Sale87.902,000175,80061,122Mar 03 03:10 PM
MARTIN JOHN CChairman and CEOMar 01Sale88.58100,0008,857,8544,019,727Mar 03 02:47 PM
Washington Robin LEVP, CFOFeb 16Sale90.726,250567,00084,688Feb 18 07:59 PM
MARTIN JOHN CChairman and CEOFeb 01Option Exercise16.40100,0001,639,5004,048,066Feb 03 05:43 PM
Carter Paul RutherfordEVP Commercial OpsFeb 01Option Exercise39.142,00078,27150,783Feb 03 05:42 PM
Carter Paul RutherfordEVP Commercial OpsFeb 01Sale82.322,000164,64048,783Feb 03 05:42 PM
MARTIN JOHN CChairman and CEOFeb 01Sale83.42100,0008,342,4753,948,066Feb 03 05:43 PM
Carter Paul RutherfordEVP Commercial OpsJan 04Option Exercise25.762,00051,52650,783Jan 06 05:08 PM
MARTIN JOHN CChairman and CEOJan 04Option Exercise16.40100,0001,639,5004,048,066Jan 06 05:21 PM
MARTIN JOHN CChairman and CEOJan 04Sale97.68100,0009,767,7083,948,066Jan 06 05:21 PM
Carter Paul RutherfordEVP Commercial OpsJan 04Sale99.202,000198,40048,783Jan 06 05:08 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSODec 15Option Exercise21.9970,0001,539,562197,936Dec 17 03:40 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSODec 15Sale102.4170,0007,168,741127,936Dec 17 03:40 PM